



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Mark Hackett**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-K-009**

Please note that we have provided this information for the period August to October 2022

You asked:

1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:

- **Abemaciclib monotherapy** – unable to split Abemaciclib patients – a total of 8 patients on all combinations.
- **Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole)** – this medication is prescribed by GPs in the community. Please contact the surgeries for their prescription data.
- **Tamoxifen monotherapy** – this medication is prescribed by GPs in the community. Please contact the surgeries for their prescription data.
- **Abemaciclib + Tamoxifen** – unable to split Abemaciclib patients – a total of 8 patients on all combinations.

2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:

- **Abemaciclib + Aromatase inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Taxane and/or Anthracycline (monotherapy or in combination)**
- **Any other active systemic anti cancer therapy**

I can confirm that SBUHB do not hold this information. Our Pharmacy systems do not record treatment by Stage – to obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

with a request for information and therefore we are withholding this information at this time.

3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:

- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent**
- **Atezolizumab +Nab-paclitaxel/Paclitaxel**
- **Pembrolizumab**
- **Sacituzumab Govitecan**
- **Parp Inhibitors (Olaparib/Talazoparib)**
- **Eribulin as a single agent or in combination**
- **Capecitabine as a single agent**
- **Platinum (e.g. carboplatin or cisplatin) as a single agent**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent**
- **Taxane and/or Anthracycline in combination**
- **Any other active systemic anti-cancer therapy**

Please see question 2

